BOSTON SCIENTIFIC CORP
For the period ended Sep 30, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 2, 2026
BSX$44.70+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| Net income (loss) | $580 | $755 | $2,823 | $2,222 |
| Other comprehensive income (loss), net of tax: | ||||
| Foreign currency translation adjustment | (6) | (28) | 212 | (719) |
| Net change in derivative financial instruments | (37) | 62 | 56 | (238) |
| Net change in defined benefit pensions and other items | (0) | (0) | 0 | (1) |
| Other comprehensive income (loss) | (44) | 34 | 268 | (957) |
| Comprehensive income (loss) | $537 | $789 | $3,092 | $1,265 |
| Net income (loss) attributable to noncontrolling interests | (2) | (0) | (6) | (4) |
| Other comprehensive income (loss) attributable to noncontrolling interests | 3 | 1 | 10 | 7 |
| Comprehensive income (loss) attributable to noncontrolling interests | 1 | 1 | 4 | 3 |
| Comprehensive income (loss) attributable to Boston Scientific common stockholders | $536 | $788 | $3,088 | $1,262 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.